Citations

Clear

5 citation(s) found for "Fox, Jean".

Role of Communication Skills Training in Enhancing Medical Education and Care for Disorders of Gut‐Brain Interaction
Petrik, Megan , FOX, J, Singh, Manavjot , Mitsuhashi, Shuji , Wang, Xiao Jing , Fox, Jean, Simonetto, Douglas A , Wang, Xiao Jing , Simonetto, Douglas A.

Mayo Clinic

Neurogastroenterology & Motility | July 18, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/nmo.70400 | PMID 42470228 Get It

Digital Therapeutic Combining Hypnosis and Diaphragmatic Breathing Intervention for Functional Abdominal Bloating: A Feasibility Study
Wang, Xiao Jing , Ebbert, Jon O. , Loftus, Conor G., Fox, Jean, Philpot, Lindsey, Ebbert, Jon, Dilmaghani, Saam , Loftus, Conor, Wang, Xiao Jing , Philpot, Lindsey M. , Palsson, Olafur S.

Mayo Clinic

Clinical and Translational Gastroenterology | February 19, 2025 | Volume: 16 | Issue: 4 | Pages: e00811

10.14309/ctg.0000000000000811 | PMID 39835688 Get It

INTRODUCTION: Abdominal bloating is a difficult symptom to treat. Hypnotherapy and diaphragmatic intervention have separately shown benefit on bloating in prior work but have not been united into a single intervention. We aimed to obtain data on the potential therapeutic impact of a novel audio-recorded bloating treatment for bloating integrating hypnosis and diaphragmatic breathing, with proposed synergistic effect. METHODS: Patients with nonorganic bowel disorders with predominant bloating symptoms completed a digitally delivered 7-session audio-recorded hypnotherapy program without clinician involvement. The intervention combined bloating-targeted hypnotic suggestions and guided diaphragmatic breathing delivered under hypnosis, and was supplemented with interval self-guided breathing exercises. Participants completed online REDCap assessments at baseline, midtreatment, at end of treatment, and 3-month follow-up, evaluating symptom severity, gastrointestinal symptom-specific anxiety, overall anxiety/depression, and quality of life. Outcomes were assessed in an intention-to-treat manner with repeated measures analysis of variances (ANOVAs) with Bonferroni-adjusted pairwise post hoc tests. RESULTS: Of 23 patients who started treatment, 22 (95.6%) completed follow-up. Bloating severity on Irritable Bowel Syndrome-Symptom Severity Scale and Patient Assessment of Upper Gastrointestinal Symptom Severity Index showed reduction in bloating with large effect sizes (Cohen d of ∼0.8) at the end of treatment, as did Visceral Sensitivity Index bloating-related anxiety. At the end of treatment, 16 patients (69.6%) were Irritable Bowel Syndrome-Symptom Severity Scale treatment responders (≥30% symptom reduction) on bloating and 17 (73.9%) on overall bowel symptom severity. Anxiety, depression, and quality-of-life scores were unchanged. Outcome measures were fully maintained at the 3-month follow-up. DISCUSSION: Results suggest the therapeutic utility of a new cost-effective self-administered bloating intervention. A randomized controlled trial is planned to confirm these therapeutic effects.
S821 Demographic Disparities of Clinical Trials Focused on Functional Gastrointestinal Disorders
Gala, Khushboo, Santiago, Hector F. Reyes, Ghusn, Wissam , Fox, Jean C. , Gala, Khushboo , Tariq, Raseen , Chedid, Victor

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S562-S563

10.14309/01.ajg.0001032652.83203.c5 Get It

Response to Oliviero et al.'s publication: “Impact of COVID‐19 lockdown on symptoms in patients with functional gastrointestinal disorders: Relationship with anxiety and perceived stress”
Wang, Xiao Jing , Murphy, Brenna M., Breen‐Lyles, Margaret K., Fox, Jean C. , Murphy, Brenna, Breen-Lyles, Margaret, Fox, Jean, Wang, Xiao Jing

Mayo Clinic

Neurogastroenterology & Motility | July 2, 2021 | Volume: 33 | Issue: 11 | Pages: No page available

10.1111/nmo.14207 | PMID 34214217 Get It

Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility
Flanagan, Eoin P. , Saito, Y. A., Lennon, Vanda A. , McKeon, Andrew , Fealey, Robert D., Szarka, Lawrence A., Foxx–Orenstein, Amy E., Fox, Jean C. , Pittock, Sean J. , Saito, Y. A., Murray, Joseph A. , Pittock, S J , Flanagan, E P , McKeon, Andrew

Mayo Clinic

Neurogastroenterology & Motility | July 21, 2014 | Volume: 26 | Issue: 9 | Pages: 1285-1297

10.1111/nmo.12391 | PMID 25039328 Get It

AbstractBackgroundChronic gastrointestinal dysmotility greatly impacts the quality of life. Treatment options are limited and generally symptomatic. Neural autoimmunity is an under‐recognized etiology. We evaluated immunotherapy as an aid to diagnosing autoimmune gastrointestinal dysmotility (AGID).MethodsTwenty‐three subjects evaluated at the Mayo Clinic for suspected AGID (August 2006–February 2014) fulfilled the following criteria: (1) prominent symptoms of gastrointestinal dysmotility with abnormalities on scintigraphy–manometry; (2) serological evidence or personal/family history of autoimmune disease; (3) treated by immunotherapy on a trial basis, 6–12 weeks (intravenous immune globulin, 16; or methylprednisolone, 5; or both, 2). Response was defined subjectively (symptomatic improvement) and objectively (gastrointestinal scintigraphy/manometry studies).Key ResultsSymptoms at presentation: constipation, 18/23; nausea or vomiting, 18/23; weight loss, 17/23; bloating, 13/23; and early satiety, 4/23. Thirteen patients had personal/family history of autoimmunity. Sixteen had neural autoantibodies and 19 had extra‐intestinal autonomic testing abnormalities. Cancer was detected in three patients. Preimmunotherapy scintigraphy revealed slowed transit (19/21 evaluated; gastric, 11; small bowel, 12; colonic, 11); manometry studies were abnormal in 7/8. Postimmunotherapy, 17 (74%) had improvement (both symptomatic and scintigraphic, five; symptomatic alone, eight; scintigraphic alone, four). Nine responders re‐evaluated had scintigraphic evidence of improvement. The majority of responders who were re‐evaluated had improvement in autonomic testing (six of seven) or manometry (two of two).Conclusions & InferencesThis proof of principle study illustrates the importance of considering an autoimmune basis for idiopathic gastrointestinal dysmotility and supports the utility of a diagnostic trial of immunotherapy.